Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

Kentaro To, Noriko Miyake, Yoji Nagasaki, Nobuyuki Shimono

Research output: Contribution to journalArticle

1 Citation (Scopus)


Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

Original languageEnglish
Pages (from-to)389-394
Number of pages6
JournalJapanese Journal of Antibiotics
Issue number6
Publication statusPublished - Dec 1 2011


All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this